Life Sciences and Health Law

The Wenger Plattner team has gained significant expertise in life sciences and health law over many years - expertise that is constantly evolving.

Life sciences and health law are complex interdisciplinary areas involving issues under both public and private law as well as specific legislation.

Our clients include hospitals, pharmaceutical, biotech and insurance companies, healthcare bodies and organisations as well as individuals.


Contact

Further specialists

Publications

Blumer Nico / Conti Carlo / Giovanoli Livio / Herzfeld Adam / Künzler Oliver / Mayoraz Jean-François / Müller Melanie

The Pharma Legal Handbook
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms · Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs · Orphan Drugs and Rare Diseases · Localization · Biosimilars and Biologics | Pharma Boardroom, 2021

Braun Martina / Conti Carlo / Künzler Oliver

GLI - Pricing & Reimbursement 2021
GLI – Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204

Braun Martina / Mayoraz Jean-François

Beurteilung der Wirtschaftlichkeit von Arzneimitteln im Rahmen der dreijährlichen Überprüfung
Urteil Bundesverwaltungsgerichts BVGer C-6093/2018 vom 17. März 2020, LSR 2020, S. 163

Braun Martina / Conti Carlo / Künzler Oliver

GLI - Pricing & Reimbursement 2020
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.



All publications